CN116249713A - 利用激活素a拮抗剂预防和治疗心功能不全和covid-19的方法 - Google Patents

利用激活素a拮抗剂预防和治疗心功能不全和covid-19的方法 Download PDF

Info

Publication number
CN116249713A
CN116249713A CN202180063332.2A CN202180063332A CN116249713A CN 116249713 A CN116249713 A CN 116249713A CN 202180063332 A CN202180063332 A CN 202180063332A CN 116249713 A CN116249713 A CN 116249713A
Authority
CN
China
Prior art keywords
activin
antibody
binding fragment
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180063332.2A
Other languages
English (en)
Chinese (zh)
Inventor
D·格拉斯
S·麦克唐内尔
J·梅格纳
L·莫顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN116249713A publication Critical patent/CN116249713A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202180063332.2A 2020-08-20 2021-08-19 利用激活素a拮抗剂预防和治疗心功能不全和covid-19的方法 Pending CN116249713A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063068251P 2020-08-20 2020-08-20
US63/068,251 2020-08-20
US202063111394P 2020-11-09 2020-11-09
US63/111,394 2020-11-09
US202163139234P 2021-01-19 2021-01-19
US63/139,234 2021-01-19
PCT/US2021/046765 WO2022040461A1 (en) 2020-08-20 2021-08-19 Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists

Publications (1)

Publication Number Publication Date
CN116249713A true CN116249713A (zh) 2023-06-09

Family

ID=77774983

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180063332.2A Pending CN116249713A (zh) 2020-08-20 2021-08-19 利用激活素a拮抗剂预防和治疗心功能不全和covid-19的方法

Country Status (10)

Country Link
US (2) US20220056119A1 (https=)
EP (1) EP4200017A1 (https=)
JP (1) JP2023539107A (https=)
KR (1) KR20230051683A (https=)
CN (1) CN116249713A (https=)
AU (1) AU2021327238A1 (https=)
CA (1) CA3189147A1 (https=)
IL (1) IL300362A (https=)
MX (1) MX2023001734A (https=)
WO (1) WO2022040461A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
JP5766179B2 (ja) 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
PT3286206T (pt) * 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
WO2018009732A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
CA3052625A1 (en) * 2017-02-06 2018-08-09 Acceleron Pharma Inc. Compositions and methods for treating heart failure
FI3600415T3 (fi) * 2017-03-24 2025-12-05 Novartis Ag Aktiviinireseptorin tyypin ii reseptorin vastainen vasta-aine käytettäväksi sydämen vajaatoiminnan hoidossa
WO2019005963A1 (en) * 2017-06-27 2019-01-03 The University Of Chicago USE OF ACTIVIN TO DETECT POST-PARTUM CARDIAC DYSFUNCTION

Also Published As

Publication number Publication date
CA3189147A1 (en) 2022-02-24
MX2023001734A (es) 2023-03-31
AU2021327238A9 (en) 2024-06-06
US20220056119A1 (en) 2022-02-24
WO2022040461A1 (en) 2022-02-24
IL300362A (en) 2023-04-01
US20250277021A1 (en) 2025-09-04
KR20230051683A (ko) 2023-04-18
JP2023539107A (ja) 2023-09-13
AU2021327238A1 (en) 2023-04-27
EP4200017A1 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
KR102146692B1 (ko) 항-ｐｄｇｆｒ-베타 항체 및 이의 용도
KR102440044B1 (ko) 항-액티빈 a 항체 및 그의 용도
KR101859911B1 (ko) 사람 ｇｄｆ８에 대한 항체
KR101781786B1 (ko) 사람 안지오포이에틴-2에 대한 고 친화성 사람 항체
KR102185516B1 (ko) Fel d1에 대한 사람 항체 및 그것의 사용방법
AU2013222203B2 (en) Anti-big-endothelin-1 (big-ET-1) antibodies and uses thereof
KR102563568B1 (ko) 렙틴 수용체에 길항하는 항원-결합 단백질
KR20170102328A (ko) 에볼라 바이러스 당단백질에 대한 인간 항체
KR20150129718A (ko) Ｇｒｅｍ 1에 대한 인간 항체
TW202417497A (zh) 活化瘦素受體的抗原結合蛋白
HUE031725T2 (en) High Human Human Protease Activated Receptor-2 Affinity
CN109922831A (zh) 通过干扰胰高血糖素受体的信号传导治疗重度胰岛素抵抗的方法
US20180057580A1 (en) Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension
KR20210022650A (ko) 항-인자 XII/XIIa 항체 및 이의 용도
US20250277021A1 (en) Methods for Preventing and Treating Cardiac Dysfunction and COVID-19 with Activin A Antagonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination